MARS Research Study - Healthy Volunteers
STUDY BASICS
This is a study for looking for healthy individuals ages 40-70 who are not diagnosed with schizophrenia spectrum disorder (SSD). This research study is being conducted at the University of Pittsburgh/UPMC to help those with schizophrenia spectrum disorder (SSD) who are suffering side effects from the use of certain medications. Compensation is provided.
STUDY PURPOSE
This is a study of Anticholinergic Burden (ACB) reduction by lowering the dose of certain medications, (known as deprescription), in individuals with mid-to-late-life Schizophrenia Spectrum Disorders (SSD). ACB is the effect of taking multiple medications that block the actions in the nervous system. The study will examine the impact of ACB reduction and its effects on cognition, functional outcome, and quality of life. You are being asked to participate as a healthy control so that we can compare results to individuals with SSD.
COULD THIS STUDY BE RIGHT FOR YOU?
- are between the ages 40-70 years
- are not diagnosed with schizophrenia spectrum disorder (SSD)
WHAT PARTICIPANTS CAN EXPECT
At the beginning of the study, and at 6-months after you have joined the study:
- interviews
- questionnaires
- blood draws
- MR imaging scans
IRB: STUDY24050090B
- Neural, molecular, and functional impacts of anticholinergic burden (ACB) reduction via deprescription in mid-to late-life patients with schizophrenia spectrum disorders (SSD)MEET THE RESEARCHER

Deepak Sarpal
Deepak K. Sarpal, M.D., completed residency training in psychiatry at The Zucker Hillside Hospital/Zucker School of Medicine at Hofstra/Northwell in 2015. He is currently an Assistant Professor in the Department of Psychiatry at the University of Pittsburgh School of Medicine where he also serves as Medical Director of the Services for the Treatment of Early Psychosis (STEP) clinic at UPMC Western Psychiatric Hospital. His research focuses on clinical outcomes of and novel treatments for psychotic disorders. His work has been supported by the National Institute of Mental Health, Brain & Behavior Research Foundation, and the Pittsburgh Foundation.